The use of gonadotropin‐releasing hormone agonist (GnRHa) as part of treatment to prevent chemotherapy‐induced premature ovarian failure has been studied in particular in breast cancer patients, and has been shown to reduce the risk regardless of hormone receptor status.26 Here, NR4A1 is linked to breast carcinoma.